**Supplementary Materials**

**Table S1.** Quality ratings of studies included in the systematic review and meta-analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Study****Authors, year** | **Selection** | **Comparability** | **Outcome** | **AHRQ****Quality****Rating** |
|  |  |  |  |  |
| Van Tricht et al., 2010 | \*\* | \* | \*\* | Fair |
| Walker et al., 2010 | \*\* | \* | \*\* | Fair |
| Bearden et al., 2011 | \*\*\* | \* | \*\*\* | Good |
| Ziermans et al., 2011 | \*\* | \* | \*\* | Fair |
| De Vylder et al., 2014 | \*\* | \* | \*\* | Fair |
| Schultze-Lutter et al., 2014 | \*\* | \* | \*\* | Fair |
| Labad et al., 2015 | \*\*\* | \* | \*\*\* | Good |
| Brucato et al., 2017 | \*\* | \* | \*\* | Fair |
| Francesconi et al., 2017 | \*\* | \* | \*\* | Fair |
| Zarogianni et al., 2019 | \*\* | \* | \*\* | Fair |
| Collin et al., 2020 | \*\*\* | \* | \*\*\* | Good |
| Modinos et al., 2020 | \*\*\* | \* | \*\*\* | Good |
| Yoviene-Sikes et al., 2020 | \*\* | \* | \*\* | Fair |
| Grent’t-Jonget al., 2021 | \*\* | \* | \*\*\* | Good |
| Kristensen et al., 2021 | \*\* | \* | \*\* | Fair |
| Pawelczyket al., 2021 | \*\* | \* | \*\* | Fair |

*Legend*: Selection, Comparability and Outcome ratings according to

the Newcastle-Ottawa Quality Assessment Form for Cohort Studies; overall quality rating

according to the Agency for Healthcare Research and Quality's (AHRQ) standards

**Figure S2.** Forest plot of transition prevalence on the basis of the cumulative sample retained at follow-up in CHR-P help-seekers who were not exposed to antidepressants at baseline. All proportions were estimated with the variance-stabilizing Freeman and Tukey double arcsine transformation.



**Figure S3**. Forest plot of transition prevalence on the basis of the cumulative sample retained at follow-up in CHR-P help-seekers who were exposed to antidepressants at baseline. All proportions were estimated with the variance-stabilizing Freeman and Tukey double arcsine transformation.



**Figure S4**. On the left, the funnel plot of the effect size (risk ratio) against its precision (the standard error); on the right, the results of the Egger's test and Begg's test for funnel plot asymmetry. Data concerns the comparison in the risk ratio of conversion to psychosis between CHR who were or were not exposed to antidepressants at baseline.

